Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

Everest Medicines has finalized an Asset Purchase Agreement with Corxel Pharmaceuticals, securing rights for the development and commercialization of LNZ100 within Greater China. This strategic move is poised to significantly bolster Everest Medicines' footprint in the ophthalmology sector.

The agreement signifies a key step for Everest Medicines in expanding its therapeutic portfolio and market reach in the region. LNZ100 is anticipated to become a valuable addition to the company's existing offerings.

This acquisition allows Everest Medicines to strengthen its position in the growing Greater China ophthalmology market by adding a promising new asset to its pipeline.